

Synthesis and Antimicrobial Activity of Novel Oxothiazolidine Derivatives

Balasaheb P. Pagar[✉]

Asian Journal of Organic & Medicinal Chemistry

Volume: 5

Year: 2020

Issue: 2

Month: April–June

pp: 91–96

DOI: <https://doi.org/10.14233/ajomc.2020.AJOMC-P248>

Received: 9 January 2020

Accepted: 17 April 2020

Published: 2 July 2020

ABSTRACT

In this article, acid hydrazide **2**, a functional group, was synthesized by the reaction of (4-chloro-12-methyl-16,17-dihydro-15-thia-6,11-diaza-cyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid ethyl ester (**1**) with hydrazine yield (4-chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid hydrazide (**2**) is discussed. The reactive acid hydrazide compound **2** was utilized for the synthesis of amides **3**, Schiff's bases **4** and thiazolidine **5** derivatives. The structures of target compounds were confirmed by elemental analysis and spectral data. The antimicrobial activity of new compounds were studied against *Streptococcus* sp., *Bacillus megaterium*, *Staphylococcus aureus*, *Escherichia coli*, *Bacillus cereus*, *Bacillus subtilis*, *Proteus vulgaris* and *Pseudomonas aeruginosa* by the agar well diffusion method. Compounds **4b**, **5a**, **5b** and **5c** showed good antimicrobial activity.

KEYWORDS

Oxothiazolidines, Heterocyclic amines, Antimicrobial activity.

INTRODUCTION

Thiazolidinone and hydrazide hydrazone derivatives are important class of heterocyclic compounds, which attract researchers to synthesize and biological evaluation of their activities. The hydrazide hydrazones mainly acts as chemotherapeutic agents, which are also useful as a building block for the synthesis of variety of heterocyclic derivatives. Thiazolidinones is a important five membered heterocyclic ring compound having sulfur at 1-position, the nitrogen at 3-position and carbonyl group at 2, 4 or 5 position. However, the hetero atoms like sulfur, nitrogen and oxygen present in the penicillin was first time recognize and characterize its occurrence in the nature [1]. The ring structure of thiazolidinone is a core component of penicillin derivatives, which shows broad spectrum of therapeutic activities. Numerous reports in the literature survey highlight their use and chemistry. The compounds of giltazones or thiazolidinone diones act as insulin sensitizers and used for the treatment of type second diabetes. Diabetic disorder is initiated due to the metabolic action caused by hyperglycemia, which is characterized due to insulin secretion deficiency [2]. An aryl thiazolidinone derivative shows hypolipidemic and hypoglycemic activities against type 2 diabetes [3,4].

There are different types of human pathogen like *S. aureus* asymptotically colonizing 30% of the human population.

Author affiliations:

Department of Chemistry, S.V.K.T. Arts, Science & Commerce College, (Affiliated to Savitribai Phule Pune University, Pune), Deolali Camp, Lam Road, Nashik-422401, India

[✉]To whom correspondence to be addressed:

E-mail: pagarbp77@gmail.com

Available online at: <http://ajomc.asianpubs.org>

Escherichia coli virulent strain causes infections like gastroenteritis, urinary tract infections, etc. Similarly, *Bacillus cereus* is a Gram-positive, beta hemolytic bacterium commonly found in soil and food are harmful to humans to cause food borne illness. To control such types of infections there are several drugs are used. The thiazolidinone derivatives showed wide spectrum of activities such as anti-hyperglycemic and anti-hyperlipidemic [5], antimicrobial [6,7], antitubercular [8], antifungal [9], anti-inflammatory [10,11], anticancer [12] and virus type 1 (HIV-1) activities [13]. 4-Thiazolidinone derivatives were reported as novel class of inhibitors of the bacterial enzyme Mur B, which was precursor for the biosynthesis of peptidoglycan [14].

Several methods were used for the synthesis of thiazolidinone derivatives are widely reported in the literature. The synthesis of thiazolidinones involves three components such as carbonyl compound, mercapto acid and amine. In the past years, the synthesis reported can be either condensation of three components in one pot or two step process. In this reaction first formation of imine derivatives by the condensation of aldehydes or ketones with amines, which undergoes attack with mercapto acid followed by intramolecular cyclization and elimination of water molecule, gives thiazolidinones [15]. Thiazolidinone derivatives also synthesized by one pot cyclocondensation of maleic acid, substituted aldehyde, thiosemicarbazide and catalytic amount of *p*-toluenesulfonic acid in dry toluene was irradiated in microwave at 100-120 °C [16].

In view of all these facts, the synthesis of bioactive heterocyclic derivatives using α -acetyl γ -butyrolactone and heterocyclic amines [17-23], enthused us to investigate new derivatives of benzo[*h*][1,6]naphthyridine for medicinal purpose. In this work, the synthesis and antimicrobial activity of novel thiazolidinone ring on the side chain of benzo[*h*]naphthyridine derivatives are reported.


EXPERIMENTAL

The melting points were measured on melting point apparatus Barnstead Electro Thermal Mod. No. IA-9200 in open capillary tubes and are uncorrected. Elemental analyses were determined using Thermo Quest Model No. flash EA 1112-Elemental Analyzer. The IR spectra of compounds were recorded on Shimadzu IR-408, instrument in potassium bromide pellets. The mass spectra were recorded on Mat 112 Varian Mat Bremen mass spectrometer. ¹H NMR (300 MHz) and ¹³C NMR (75 MHz) spectra were recorded on VARIAN XL-300 instrument at 25 °C. The measurements were done using solvents-CDCl₃ and DMSO-*d*₆ with TMS as an internal standard reference. Coupling constants (*J*) are quoted to the nearest 0.1 Hz and chemical shift (δ scale) are quoted in parts per million (ppm).

Compound **1** was synthesized according to our reported work [17].

(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid hydrazide (2): A reaction mixture of (4-chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)-acetic acid ethyl ester (**1**) (4.04 mL, 0.01 mol), hydrazine (0.384 g, 0.012 mol) and five drops of acetic acid in absolute ethanol was refluxed for 20 h. The reaction progress was continuously checked by TLC using toluene/ethyl acetate (2:8) till the reactant

was consumed. After completion of the reaction, the obtained product was filtered and washed with little ethanol (**Scheme-I**). Compound **2** was recrystallized in DMF gave yellow coloured prisms (3.12 g, 80%, mp 201 °C); *R*_f 0.29 (ethyl acetate/toluene 8:2); IR (KBr, ν_{\max} , cm⁻¹): 3292 (NH), 3203 (NH₂), 2916, 2829, 1662 (C=O), 1545, 1483, 1307, 1084, 775; ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.76 (s, 3H, CH₃), 3.47 (t, *J* = 7.4 Hz, 2H, CH₂C-H₂S), 3.57 (t, *J* = 7.4 Hz, 2H, CH₂CH₂S), 4.28 (s, 2H, CH₂), 4.42 (s, 2H, NH₂, exchangeable with D₂O), 7.40 (t, *J* = 8.0 Hz, 1H, C₂H), 7.73 (d, *J* = 8.0 Hz, 1H, C₃H), 8.91 (d, *J* = 8.0Hz, 1H, C₁H), 9.31 (s, 1H, NH, exchangeable with D₂O); MS: *m/z* (%): 392 (M+2, 50), 390 (M+, 90), 323 (100), 232 (45), 199 (40), 116 (30), 100 (10). Anal. calcd. (found) % for C₁₇H₁₅N₄OS₂Cl (m.w. 390.92): C, 52.23 (52.32); H, 3.87 (3.89); N, 9.07 (9.02).



Scheme-I: Reagents and conditions: (i) NH₂NH₂, EtOH, AcOH, reflux, 20 h; (ii) ArCOOH, AcOH, reflux, 3 h; (iii) ArCHO, EtOH, AcOH, 80 °C, 5 h; (iv) EtOH, Anhydrous ZnCl₂, reflux, 5 h

4-Chloro-12-methyl-7-(phenyl-[1,3,4]-oxadiazol-2-ylmethylsulfanyl)-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthrene (3a-d): A solution of (4-chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid hydrazine (**2**) (0.390 g, 0.001 mol), respective aryl acid (0.0012 mol) and sulfuric acid (1 mL) was refluxed for 5 h in 10 mL acetic acid. The reaction progress was continuously monitored by using TLC in toluene/ethyl acetate (2:8) till the reactant was consumed. The reaction mixture was cooled to room temperature after completion. The solid was filtered, recrystallized in DMF to give compound **3a-d** (**Scheme-I**).

4-Chloro-12-methyl-7-(5-*p*-tolyl-[1,3,4]oxadiazol-2-ylmethylsulfanyl)-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthrene (3a): Pink prisms; yield (0.416 g, 85%, m.p. 323 °C); *R*_f 0.28 (ethyl acetate/toluene 8:2); IR (KBr, ν_{\max} , cm⁻¹): 3188, 3130 (NH), 1656, 1647 (C=O), 1548, 1330, 802; ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.34 (s, 3H, CH₃), 2.75 (s, 3H, CH₃), 3.49 (t, *J* = 7.2 Hz, 2H, CH₂CH₂S), 3.53 (t, *J* =

7.2 Hz, 2H, CH₂CH₂S), 4.35 (s, 2H, CH₂), 7.12 (d, *J* = 7.5 Hz, 2H, ArH), 7.38 (d, *J* = 7.5 Hz, 2H, ArH), 7.51 (t, *J* = 7.3 Hz, 1H, C₂H), 7.81 (d, *J* = 7.3 Hz, 1H, C₃H), 8.92 (d, *J* = 7.3 Hz, 1H, C₁H), 9.91 (s, 1H, NH, exchangeable with D₂O), 9.95 (s, 1H, NH, exchangeable with D₂O); MS: *m/z* (%): 510 (M+2, 30), 508 (M+, 100), 473 (20), 389 (30), 359 (40), 317 (50), 191 (80), 149 (30), 119 (20). Anal. calcd. (found) % for C₂₅H₂₁N₄O₂S₂Cl (m.w. 509.05): C, 58.99 (58.91); H, 4.16 (4.18); N, 11.01 (11.04).

4-Chloro-7-(5-(3-chlorophenyl)[1,3,4]oxadiazol-2-ylmethylsulfanyl)-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthrene (3b): Pink prisms; Yield: 0.408 g, 80%, m.p. 319 °C; R_f 0.29 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max}, cm⁻¹): 3178, 3141 (NH), 3045, 1654, 1643 (C=O), 1556, 1332, 804; ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.73 (s, 3H, CH₃), 3.45 (t, *J* = 7.4 Hz, 2H, CH₂CH₂S), 3.55 (t, *J* = 7.4 Hz, 2H, CH₂CH₂S), 4.36 (s, 2H, CH₂), 7.08-7.32 (m, 3H, ArH), 7.20 (s, 1H, ArH), 7.53 (t, *J* = 7.6 Hz, 1H, C₂H), 7.77 (d, *J* = 7.6 Hz, 1H, C₃H), 8.91 (d, *J* = 7.6 Hz, 1H, C₁H), 9.93 (s, 1H, NH, exchangeable with D₂O), 9.97 (s, 1H, NH, exchangeable with D₂O); MS: *m/z* (%): 532 (M+4, 20), 530 (M+2, 40), 528 (M+, 100), 458 (30), 389 (40), 359 (30), 325 (30), 211 (90), 169 (60), 139 (70). Anal. calcd. (found) % for C₂₄H₁₈N₄O₂S₂Cl₂ (m.w. 529.47): C, 54.44 (54.40); H, 3.43 (3.38); N, 10.58 (10.47).

4-Chloro-7-(5-phenyl[1,3,4]oxadiazol-2-ylmethylsulfanyl)-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthrene (3c): Faint pink coloured prisms; yield: 0.356 g, 70%; m.p. 305 °C; R_f 0.23 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max}, cm⁻¹): 3140, 3096 (NH), 3024, 1659, 1650 (C=O), 1543, 1320, 807; ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.68 (s, 3H, CH₃), 3.38 (t, *J* = 7.3 Hz, 2H, CH₂CH₂S), 3.52 (t, *J* = 7.3 Hz, 2H, CH₂CH₂S), 4.20 (s, 2H, CH₂), 7.02-7.20 (m, 5H, ArH), 7.51 (t, *J* = 6.5 Hz, 1H, C₂H), 7.70 (d, *J* = 6.5 Hz, 1H, C₃H), 8.90 (d, *J* = 6.5 Hz, 1H, C₁H), 9.92 (s, 1H, NH, exchangeable with D₂O), 9.95 (s, 1H, NH, exchangeable with D₂O); MS: *m/z* (%): 496 (M+2, 40), 494 (M+, 100), 390 (40), 324 (30), 178 (40), 138 (60). Anal. calcd. (found) % for C₂₄H₁₉N₄O₂S₂Cl (m.w. 494.06): C, 58.23 (58.10); H, 3.87 (3.80); N, 11.32 (11.29).

4-Chloro-7-(5-(4-chlorophenyl)[1,3,4]oxadiazol-2-ylmethylsulfanyl)-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthrene (3d): Faint brown coloured prisms; yield: 0.343 g, 65%, m.p. 296 °C; R_f 0.32 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max}, cm⁻¹): 3159, 3120 (NH), 3010, 1656, 1643 (C=O), 1542, 1350, 810; ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.60 (s, 3H, CH₃), 3.36 (t, *J* = 7.4 Hz, 2H, CH₂CH₂S), 3.47 (t, *J* = 7.4 Hz, 2H, CH₂CH₂S), 4.30 (s, 2H, CH₂), 7.18-7.30 (m, 4H, ArH), 7.46 (t, *J* = 6.8 Hz, 1H, C₂H), 7.68 (d, *J* = 6.8 Hz, 1H, C₃H), 8.95 (d, *J* = 6.8 Hz, 1H, C₁H), 9.85 (s, 1H, NH, exchangeable with D₂O), 9.90 (s, 1H, NH, exchangeable with D₂O); MS: *m/z* (%): 532 (M+4, 25), 530 (M+2, 30), 528 (M+, 100), 456 (20), 390 (30), 324 (30), 178 (30), 168 (50), 139 (60). Anal. calcd. (found) % for C₂₄H₁₈N₄O₂S₂Cl₂ (m.w. 529.47): C, 54.44 (54.50); H, 3.43 (3.48); N, 10.58 (10.52).

(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid substituted benzylidene-hydrazide (4a-d): A solution of (4-chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]-

phenanthren-7-ylsulfanyl)acetic acid hydrazide (**2**) (1.95 g, 0.005 mol), aryl aldehyde (0.006 mol) and five drops of acetic acid in absolute ethanol (15 mL) was heated to reflux for 3.5 h. The progress of the reaction was checked by using TLC in toluene/ethyl acetate (2:8) till the reactant was consumed. After completion, the solid obtained was suction filtered and washed with ethanol, recrystallized in DMF to give compounds **4a-d** in good yield (**Scheme-I**).

(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid benzylidene-hydrazide (4a): Pink prisms; yield: 1.79 g, 75%; m.p.: 265-266 °C; R_f 0.68 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max}, cm⁻¹): 3244 (NH), 1679 (CO), 1610, 1552, 1438, 1166, 954; ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.34 (s, 3H, CH₃), 3.48 (t, *J* = 7.2 Hz, 2H, CH₂CH₂S), 3.60 (t, *J* = 7.2 Hz, 2H, CH₂CH₂S), 4.85 (s, 2H, CH₂), 7.34-7.47 (m, 3H, ArH), 7.54 (t, *J* = 7.8 Hz, 1H, C₂H), 7.67-7.73 (m, 2H, ArH), 7.85 (d, *J* = 7.7 Hz, 1H, C₃H), 8.04 (s, 1H, N=CH), 8.84 (d, *J* = 7.8 Hz, 1H, C₁H), 11.67 (s, 1H, NH, exchangeable with D₂O); MS: *m/z* (%): 481 (M+2, 20), 479 (M+, 100), 375 (30), 360 (40), 320 (40), 318 (60), 201 (40), 161 (70), 119 (70). Anal. calcd. (found) % for C₂₄H₁₉N₄OS₂Cl (m.w. 479.03): C, 60.18 (60.14); H, 4.01 (4.07); N, 11.71 (11.64).

(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid (3,4-dimethoxy benzylidene)hydrazide (4b): Pink prisms; yield: 1.88 g, 70%; m.p. 244-245 °C; R_f 0.70 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max}, cm⁻¹): 3213 (NH), 3043, 2898, 1666 (CO), 1550, 1506, 1297, 1024; ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.38 (s, 3H, CH₃), 3.50 (t, *J* = 7.3 Hz, 2H, CH₂CH₂S), 3.61 (t, *J* = 7.3 Hz, 2H, CH₂CH₂S), 3.76 (s, 3H, OCH₃), 3.79 (s, 3H, OCH₃), 4.82 (s, 2H, CH₂), 6.97 (d, *J* = 7.0 Hz, 1H, ArH), 7.21-7.27 (m, 2H, ArH), 7.53 (t, *J* = 8.4 Hz, 1H, C₂H), 7.87 (d, *J* = 8.4 Hz, 1H, C₃H), 7.97 (s, 1H, N=CH), 8.81 (d, *J* = 8.4 Hz, 1H, C₁H), 11.83 (s, 1H, NH, exchangeable with D₂O); MS: *m/z* (%): 541 (M+2, 30), 539 (M+, 100), 508 (40), 477 (50), 375 (40), 252 (50), 220 (90), 178 (80), 121 (40). Anal. calcd. (found) % for C₂₆H₂₃N₄O₃S₂Cl (m.w. 539.08): C, 57.93 (57.88); H, 4.30 (4.35); N, 10.39 (10.35).

(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid (3-nitro-benzylidene)hydrazide (4c): Pink prisms; yield: 1.83 g, 70%; m.p. 251-252 °C; R_f 0.68 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max}, cm⁻¹): 3215 (NH), 3030, 2910, 1680 (CO), 1606, 1530, 1295, 1020; ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.36 (s, 3H, CH₃), 3.51 (t, *J* = 7.2 Hz, 2H, CH₂CH₂S), 3.60 (t, *J* = 7.2 Hz, 2H, CH₂CH₂S), 4.86 (s, 2H, CH₂), 7.53 (t, *J* = 8.1 Hz, 1H, C₂H), 7.70 (t, *J* = 6.8 Hz, 1H, ArH), 7.83 (d, *J* = 7.9 Hz, 1H, C₃H), 8.18 (s, 1H, N=CH), 8.20-8.35 (m, 3H, ArH), 8.84 (d, *J* = 7.9 Hz, 1H, C₁H), 11.91 (s, 1H, NH, exchangeable with D₂O); MS: *m/z* (%): 527 (M+2, 30), 525 (M+, 60), 479 (30), 444 (30), 376 (50), 208 (60), 206 (100), 178 (40), 125 (50). Anal. calcd. (found) % for C₂₄H₂₀N₅O₃S₂Cl (m.w. 526.04): C, 54.80 (54.85); H, 3.83 (3.79); N, 13.31 (13.36).

(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid (4-chlorobenzylidene)hydrazide (4d): Pink prisms; yield (1.86 g, 73%, mp 281 °C); R_f 0.73 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max}, cm⁻¹): 3240 (NH), 3203, 3068, 1676 (CO), 1600,

1515, 1438, 1166, 954; ^1H NMR (300 MHz, DMSO- d_6): δ 3.36 (s, 3H, CH₃), 3.49 (t, $J = 7.4$ Hz, 2H, CH₂CH₂S), 3.60 (t, $J = 7.4$ Hz, 2H, CH₂CH₂S), 4.82 (s, 2H, CH₂), 7.43-7.53 (m, 3H, ArH, C₂H), 7.71-7.75 (m, 2H, ArH), 7.83 (d, $J = 7.8$ Hz, 1H, C₃H), 8.11 (s, 1H, N=CH), 8.81 (d, $J = 7.9$ Hz, 1H, C₁H), 11.71 (s, 1H, NH, exchangeable with D₂O); MS: m/z (%): 517 (M+4, 20), 515 (M+2, 80), 513 (M+, 90), 369 (20), 368 (30), 367 (100), 339 (15), 324 (15), 311 (10). Anal. calcd. (found) % for C₂₄H₁₈N₄OS₂Cl₂ (m.w. 513.47): C, 56.14 (56.11); H, 3.53 (3.56); N, 10.91 (10.87).

2-(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)-*N*-(2-(phenyl-4-oxo-2-phenyl-thiazolidin-3-yl)acetamide (5a-c): Compound **4a-c** (0.553 g, 0.001 mol) was refluxed with thioglycolic acid (0.138 g, 0.002 mol) in presence of anhydrous ZnCl₂ (0.135 g, 0.001 mol) in dry ethanol (25 mL) for 5 h. The reaction progress was checked by TLC in toluene/ethyl acetate (2:8) till the reactant was consumed. After completion the mixture of reaction was cooled, the solid obtained was filtered and recrystallized in DMF to furnished compound **5a-c** in good yield (Scheme-I).

2-(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)-*N*-(4-oxo-2-phenyl-thiazolidin-3-yl)acetamide (5a): Pink prisms; yield: 0.392 g, 71%; m.p.: 239-241 °C; R_f 0.30 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max} , cm⁻¹): 3320 (NH), 3010, 2917, 1730 (C=O), 1703 (C=O), 1546, 1309, 1170, 952; ^1H NMR (300 MHz, DMSO- d_6): δ 3.33 (s, 3H, CH₃), 3.48 (t, $J = 7.0$ Hz, 2H, CH₂CH₂S), 3.59 (t, $J = 7.0$ Hz, 2H, CH₂CH₂S), 4.30 (s, 2H, CH₂), 4.83 (s, 2H, CH₂), 4.93 (s, 1H, CH), 7.27-7.39 (m, 3H, ArH), 7.53 (t, $J = 7.7$ Hz, 1H, C₂H), 7.61-7.71 (m, 2H, ArH), 7.83 (d, $J = 7.7$ Hz, 1H, C₃H), 8.91 (d, $J = 7.6$ Hz, 1H, C₁H), 11.89 (s, 1H, NH, exchangeable with D₂O); MS: m/z (%): 555 (M+2, 20), 553 (M+, 40), 518 (30), 476 (20), 366 (30), 235 (100), 193 (90), 178 (70), 122 (40). Anal. calcd. (found) % for C₂₆H₂₁N₄O₂S₃Cl (m.w. 553.13): C, 56.47 (56.40); H, 3.82 (3.80); N, 10.12 (10.15).

2-(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)-*N*-[2-(3,4-dimethoxyphenyl)-4-oxothiazolidin-3-yl]-acetamide (5b): Pink prisms; yield: 0.410 g, 67%, m.p.: 243-244 °C; R_f 0.40 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max} , cm⁻¹): ν 3309 (NH), 2912, 1714 (C=O), 1703 (C=O), 1546, 1307, 1085, 950; ^1H NMR (300 MHz, DMSO- d_6): δ 3.36 (s, 3H, CH₃), 3.51 (t, $J = 7.4$ Hz, 2H, CH₂CH₂S), 3.60 (t, $J = 7.4$ Hz, 2H, CH₂CH₂S), 3.75 (s, 3H, OCH₃), 3.78 (s, 3H, OCH₃), 4.30 (s, 2H, CH₂), 4.83 (s, 2H, CH₂), 4.97 (s, 1H, CH), 7.05-7.21 (m, 3H, ArH), 7.55 (t, $J = 7.8$ Hz, 1H, C₂H), 7.85 (d, $J = 7.8$ Hz, 1H, C₃H), 8.81 (d, $J = 7.8$ Hz, 1H, C₁H), 11.91 (s, 1H, NH, exchangeable with D₂O); MS: m/z (%): 615 (M+2, 20), 613 (M+, 60), 551 (40), 313 (60), 281 (100), 239 (40), 224 (30), 137 (40). Anal. calcd. (found) % for C₂₈H₂₅N₄O₄S₃Cl (m.w. 613.18): C, 54.85 (54.86); H, 4.11 (4.16); N, 9.14 (9.16).

2-(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)-*N*-[2-(3-nitrophenyl)-4-oxothiazolidin-3-yl]-acetamide (5c): Pink prisms; yield: 0.426 g, 71%; m.p. 354 °C; R_f 0.43 (ethyl acetate/toluene 8:2); IR (KBr, ν_{max} , cm⁻¹): 3188 (NH), 3047, 2950, 1695 (C=O), 1666 (C=O), 1533, 1433, 1271, 954; ^1H NMR (300

MHz, DMSO- d_6): δ 3.37 (s, 3H, CH₃), 3.50 (t, $J = 7.3$ Hz, 2H, CH₂CH₂S), 3.61 (t, $J = 7.3$ Hz, 2H, CH₂CH₂S), 4.40 (s, 2H, CH₂), 4.82 (s, 2H, CH₂), 5.03 (s, 1H, CH), 7.54 (t, $J = 8.1$ Hz, 1H, C₂H), 7.69 (t, $J = 6.5$ Hz, 1H, ArH), 7.88 (d, $J = 8.1$ Hz, 1H, C₃H), 8.22-8.40 (m, 3H, ArH), 8.82 (d, $J = 8.0$ Hz, 1H, C₁H), 11.91 (s, 1H, NH, exchangeable with D₂O); MS: m/z (%): 601 (M+2, 20), 599 (M+, 70), 425 (20), 317 (20), 208 (100), 166 (60), 151 (70). Anal. calcd. (found) % for C₂₆H₂₂N₅O₄S₃Cl (m.w. 600.14): C, 52.04 (52.01); H, 3.70 (3.74); N, 11.67 (11.65).

Antibacterial activity: Antibacterial activities were investigated using agar well diffusion method. The activity of tested samples was studied against the eight bacteria species, namely, *Staphylococcus aureus*, *Escherichia coli*, *Bacillus subtilis*, *Pseudomonas aeruginosa*, *Proteus vulgaris*, *Bacillus cereus*, *Streptococcus sp aureus* and *Bacillus megaterium*. Centrifuged pellets of bacteria from a 24 h old culture containing approximately 10⁴-10⁶ CFU/mL were spread on the surface of nutrient agar (typton 1%, yeast extract 0.5%, NaCl 0.5%, agar 1%, 1000 mL of distilled water, pH 7), which was autoclaved under 121 °C for at least 20 min. Wells were created in medium with the help of a sterile metallic bores and then cooled down to 45 °C. The activity was determined by measuring the diameter of the inhibition zone (in mm). Test samples prepared in DMF (10 mg/mL) were loaded into the wells of the plates. DMF was loaded as control. The plates were kept for incubation at 37 °C for 24 h and then the plates were examined for the formation of zone of inhibition. The test was performed three times for each bacterium culture. Ampicillin and streptomycin was used as antibacterial standard drugs.

RESULTS AND DISCUSSION

(4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid ethyl ester **1** on reaction with hydrazine hydrochloride in acidic medium gave acid hydrazide derivative **2** in 80% yield. No reaction progress was observed in absence of acid catalyst. The structure of newly synthesized compounds was established by analytical and spectral data. The IR spectrum of compound **2** shows stretching frequency at 1662 (C=O), 3292 (NH), 3203 cm⁻¹ (NH₂). The ^1H NMR spectrum in DMSO- d_6 of compound **2** showed the broad singlet at δ 4.42 ppm was assignable for NH₂ and at δ 9.31 ppm was assignable for NH protons. The CH₂ group was deshielded at 4.28 ppm due to attach with electro negative sulfur and carbonyl group. The doublet at 2.76 & 3.47 ppm was assignable for the protons of CH₂CH₂S group respectively. The remaining protons showed expected splitting pattern and chemical shifts. Compound **2** on reaction with aromatic acid in presence of small amount of sulfuric acid in AcOH as solvent furnished compound **3a-b** in 80-85% yield. Here also the reaction does not observed in absence of H₂SO₄ catalyst. The same reaction in POCl₃ furnishes inseparable mixture of products. The IR spectrum of compound **3a** shows stretching frequency at 1647, 1656 (C=O), 3188-3130 cm⁻¹ (NH). The ^1H NMR spectrum in DMSO- d_6 of compound **3a** showed the resonance singlet at δ 9.91 & 9.95 ppm was assignable for NH protons. On refluxing compound **2** with aryl aldehydes in presence of AcOH in dry ethanol furnished compound **4a-c** in 70-75% yields. The structures of **4a-c** were established by analytical

TABLE-1
ANTIMICROBIAL ACTIVITY OF SYNTHESIZED COMPOUNDS SCREEN AGAINST BACTERIAL SPECIES

Compd. No.	Antibacterial inhibition zone diameter (mm)							
	<i>P. aeruginosa</i>	<i>B. subtilis</i>	<i>E. coli</i>	<i>S. aureus</i>	<i>B. cereus</i>	<i>P. vulgaris</i>	<i>B. megaterium</i>	<i>Streptococcus</i> sp
2	–	–	–	–	–	–	–	–
3a	–	–	–	–	–	–	–	–
3b	–	–	–	–	–	–	–	–
3c	–	–	8	–	–	–	–	–
3d	–	–	–	–	8	–	–	–
4a	–	8	10	–	–	–	–	–
4b	–	14	13	–	10	17	15	8
4c	–	13	–	8	–	–	–	–
4d	–	–	–	–	–	–	–	–
5a	16	17	13	12	10	16	16	10
5b	8	16	8	17	16	11	–	8
5c	–	15	–	16	13	–	40	–
Ampicillin	45	40	35	45	33	34	15	40
Streptomycin	–	15	–	13	40	34	–	–

& spectral data. IR of **4a** showed stretching at 1680-1666 cm^{-1} (amide) and 3244-3213 cm^{-1} (NH). The ^1H NMR (DMSO- d_6) spectrum of compound **4a** showed the resonance singlet at δ 8.04 ppm was assignable for N=CH and at δ 11.67 ppm was assignable for NH, the remaining protons showed expected splitting pattern and chemical shifts. The EIMS showed M+ (479) and M+2 (481) m/z , indicating the presence of one chlorine atom. 4-Chloro-12-methyl-16,17-dihydro-15-thia-6,11-diazacyclopenta[*a*]phenanthren-7-ylsulfanyl)acetic acid benzylidene hydrazides **4a-c** on refluxing with thioglycolic acid in presence of one equivalent anhydrous ZnCl_2 in ethanol furnished compound **5a-c** in good yields. The excess amount of catalyst ZnCl_2 do not alter the rate of reaction but create difficulty in product purification, while lower amount than 1 equivalent decrease the rate of reaction. Other catalyst AlCl_3 or H_2SO_4 gave mixture of inseparable mixture of products. The IR spectrum of compound **5a** shows carbonyl stretching frequency at 1703, 1730 cm^{-1} and NH at 3320 cm^{-1} . The ^1H NMR spectrum in DMSO- d_6 of compound **5a** showed the highly deshielded singlet at δ 11.89 ppm was assignable for NH protons. The remaining protons showed expected splitting pattern and chemical shifts.

Antimicrobial activity: The synthesized compounds screened against the cultures of different bacterial species, namely, *Bacillus megaterium*, *Staphylococcus aureus*, *Proteus vulgaris*, *Escherichia coli*, *Bacillus subtilis*, *Pseudomonas aeruginosa*, *Bacillus cereus* and *Streptococcus* sp. were screen for antimicrobial activity. The agar well diffusion technique was used to study antimicrobial activities. Compounds **4b**, **5a**, **5b** and **5c** showed good activity against the different bacterial strains. The bacterial organisms were screened in solutions of compound having concentration; 1.0 mg/mL. Ampicillin and streptomycin as a reference compounds were used against antibacterial species to evaluate the activity of synthesized compounds under similar conditions. The minimum inhibitory concentrations (MIC) of the synthesized compounds were measured by two-fold dilution method. The screening results are depicted in Table-1. Compound **5a**, **5b** and **5c** having pharmacologically active thiazolidin ring on side chain of cyclopenta[*a*]phenanthrene. Also the substituent 3-phenyl, 3,4-dimethoxyphenyl and 3-nitrophenyl on thiazolidin ring showed increasing activity.

Compound **5c** showed good activity against *Bacillus megaterium* species than the standard ampicillin and streptomycin.

Conclusion

A convenient synthesis of benzo[*h*][1,6]naphthyridines and cyclopenta[*a*]phenanthrens as a useful tool in the development of iminoether and iminothioether derivatives was disclosed. The synthesized thiazolidine derivative on the side chain of cyclopenta[*a*]phenanthren moiety was achieved by FGI reaction. The antimicrobial activity study revealed that compounds **3d**, **3h** and **5a-c** exhibited a good antimicrobial activity. Thiazolidine derivative **5c** showed excellent activity against *Bacillus megaterium*.

ACKNOWLEDGEMENTS

The author thanks to U.G.C. New Delhi and B.C.U.D. University of Pune, India for financial support to this research project. Author also thanks to Department of Chemistry, University of Pune, IIT Mumbai and Principal K.T.H.M. College Nashik, India for spectral and analytical facilities.

REFERENCES

- A.K. Jain, A. Vaidya, V. Ravichandran, S.K. Kashaw and R.K. Agrawal, Recent Developments and Biological Activities of Thiazolidinone Derivatives: A Review, *Bioorg. Med. Chem.*, **20**, 3378 (2012); <https://doi.org/10.1016/j.bmc.2012.03.069>
- M.J. Nanjan, M. Mohammed, B.R. Prashantha Kumar and M.J.N. Chandrasekar, Thiazolidinediones as Antidiabetic Agents: A Critical Review, *Bioorg. Chem.*, **77**, 548 (2018); <https://doi.org/10.1016/j.bioorg.2018.02.009>
- A. Ahmadi, M. Khalili, S. Samavat, E. Shahbazi and B. Nahri-Niknafs, Synthesis and Evaluation of the Hypoglycemic and Hypolipidemic Activity of Novel Arylidene Thiazolidinedione Analogson a Type 2 Diabetes Model, *Pharm. Chem. J.*, **50**, 165 (2016); <https://doi.org/10.1007/s11094-016-1416-z>
- N. Thangavel, M. Al-Bratty, S.A. Javed, W. Ahsan and H.A. Alhazmi, Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs, *Int. J. Med. Chem.*, **2017**, 1069718 (2017); <https://doi.org/10.1155/2017/1069718>
- S.K. Shrivastava, A. Batham, S.K. Sinha, T.K. Parida, D. Garabadu and P.K. Choubey, Design, Synthesis and Evaluation of Novel Thiazolidinedione Derivatives as Anti-Hyperglycemic and Anti-Hyperlipidemic Agents, *Med. Chem. Res.*, **25**, 2258 (2016); <https://doi.org/10.1007/s00044-016-1675-y>

6. A.S. Chavan, A.S. Kharat, M.R. Bhosle and R.A. Mane, Baker's Yeast Catalyzed One-Pot Synthesis of Bioactive 2-[Benzylidene(or Pyrazol-4-yl-methylene)hydrazono]-1,3-thiazolidin-4-one-5-yl-acetic Acids, *Heterocycl. Commun.*, **24**, 103 (2018); <https://doi.org/10.1515/hc-2017-0130>
7. P.K. Sharma, N. Chandak, P. Kumar, C. Sharma and K.R. Aneja, Synthesis and Biological Evaluation of Some 4-Functionalized Pyrazoles as Antimicrobial Agents, *Eur. J. Med. Chem.*, **46**, 1425 (2011); <https://doi.org/10.1016/j.ejmech.2011.01.060>
8. A.R. Deshmukh, S.T. Dhumal, L.U. Nawale, V.M. Khedkar, D. Sarkar and R.A. Mane, Dicationic Liquid Mediated Synthesis of Tetrazoloquinolinyl Methoxy Phenyl 4-thiazolidinones and their Antibacterial and Antitubercular Evaluation, *Synth. Commun.*, **49**, 587 (2019); <https://doi.org/10.1080/00397911.2018.1564928>
9. G. Capan, N. Ulusoy, N. Ergenc and M. Kiraz, New 6-Phenylimidazo[2,1-*b*]thiazole Derivatives: Synthesis and Antifungal Activity, *Monatsh. Chem.*, **130**, 1399 (1999); <https://doi.org/10.1007/PL00010200>
10. A. Ceriello, Thiazolidinediones as Anti-inflammatory and Anti-atherogenic Agents, New 6-Phenylimidazo[2,1-*b*]thiazole Derivatives: Synthesis and Antifungal Activity, *Diabetes Metab. Res. Rev.*, **24**, 14 (2008); <https://doi.org/10.1002/dmrr.790>
11. C. Dwivedi, T.K. Gupta and S.S. Parmar, Substituted Thiazolidones as Anticonvulsants, *J. Med. Chem.*, **15**, 553 (1972); <https://doi.org/10.1021/jm00275a031>
12. H.N. Hafez and A.R. El-Gazzar, Synthesis and Antitumor Activity of Substituted Triazol[4,3-*a*]pyrimidin-6-sulfonamide with an Incorporated Thiazolidinone Moiety, *Bioorg. Med. Chem. Lett.*, **19**, 4143 (2009); <https://doi.org/10.1016/j.bmcl.2009.05.126>
13. L. Barreca, A. Chimirri, L. De Luca, A.-M. Monforte, P. Monforte, A. Rao, M. Zappalà, J. Balzarini, E. De Clercq, C. Pannecouque and M. Witvrouw, *Bioorg. Med. Chem. Lett.*, **11**, 1793 (2001); [https://doi.org/10.1016/S0960-894X\(01\)00304-3](https://doi.org/10.1016/S0960-894X(01)00304-3)
14. C.J. Andres, J.J. Bronson, S.V. D'Andrea, M.S. Deshpande, P.J. Falk, K.A. Grant-Young, W.E. Harte, H.-T. Ho, P.F. Misco, J.G. Robertson, D. Stock, Y. Sun and A.W. Walsh, *Bioorg. Med. Chem. Lett.*, **10**, 715 (2000); [https://doi.org/10.1016/S0960-894X\(00\)00073-1](https://doi.org/10.1016/S0960-894X(00)00073-1)
15. L. Popiolek, I. Piatkowska-Chmiel, M. Gawronska-Grzywacz, A. Biernasiuk, M. Izdebska, M. Herbet, M. Sysa, A. Malm, J. Dudka and M. Wujec, New Hydrazone-Hydrazones and 1,3-Thiazolidin-4-ones with 3-Hydroxy-2-naphthoic Moiety: Synthesis, *in vitro* and *in vivo* Studies, *Biomed. Pharmacother.*, **103**, 1337 (2018); <https://doi.org/10.1016/j.biopha.2018.04.163>
16. C. Saiz, C. Pizzo, E. Manta, P. Wipf and S.G. Mahler, Microwave-Assisted Tandem Reactions for the Synthesis of 2-Hydrazolyl-4-thiazolidinones, *Tetrahedron Lett.*, **50**, 901 (2009); <https://doi.org/10.1016/j.tetlet.2008.12.020>
17. R.B. Toche, B.P. Pagar, R.R. Zoman, G.B. Shinde and M.N. Jachak, Synthesis of Novel Benzo[*h*][1,6]naphthyridine Derivatives from 4-Aminoquinoline and Cyclic β -Ketoester, *Tetrahedron*, **66**, 5204 (2010); <https://doi.org/10.1016/j.tet.2010.04.085>
18. R.B. Toche, B.K. Ghotekar, M.A. Kazi and M.N. Jachak, Synthesis of Benzohetero[3,2-*a*]pyrimidines using Cyclic β -Keto Lactone as a Building Block, *Monatsh. Chem.*, **140**, 235 (2009); <https://doi.org/10.1007/s00706-008-0062-x>
19. R.B. Toche, B.K. Ghotekar, D.B. Kendre, M.A. Kazi and M.N. Jachak, An Efficient Synthesis of Pyrazolo[3,4-*b*]pyrrolo[2,3-*d*]pyridines from 5-Aminopyrazoles and Cyclic β -Keto ester, *J. Heterocycl. Chem.*, **45**, 1711 (2008); <https://doi.org/10.1002/jhet.5570450624>
20. R.B. Toche, B.K. Ghotekar, M.A. Kazi, S.P. Patil and M.N. Jachak, New Approach for the Synthesis of Pyrido[1,2-*a*]pyrimidines, *Schol. Res. Exch.*, **2008**, 434329 (2008); <https://doi.org/10.3814/2008/434329>
21. B.K. Ghotekar, M.A. Kazi, M.N. Jachak and R.B. Toche, Effect of Substituents on Absorption and Fluorescence Properties of Pyrazolo[3,4-*b*]pyrrolo[2,3-*d*]pyridines, *Can. J. Chem.*, **86**, 1070 (2008); <https://doi.org/10.1139/v08-155>
22. R.B. Toche, B.K. Ghotekar, M.A. Kazi, D.B. Kendre and M.N. Jachak, Synthesis of Fused Pyrimidines from Amines and Cyclic β -Formylesters, *Tetrahedron*, **63**, 8157 (2007); <https://doi.org/10.1016/j.tet.2007.05.123>
23. R.V. Rote, D.P. Shelar, S.R. Patil, S.S. Shinde, R.B. Toche and M.N. Jachak, Effect of Donor-Acceptor Chromophores on Photophysical Properties of Newly Synthesized Pyrazolo-Pyrrolo-Pyrimidines (PPP), *J. Fluoresc.*, **21**, 453 (2011); <https://doi.org/10.1007/s10895-010-0704-3>